Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13484037.14861147 ◽

2012 ◽

Author(s):

Thomas Powles

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

The Journal of Urology ◽

10.1016/j.juro.2012.04.069 ◽

2012 ◽

Vol 188 (2) ◽

pp. 412-413

Author(s):

Samir S. Taneja

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Commentary on “Comparative effectiveness of axitinib vs. sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase 3 trial.” B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D. Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim, R.J. Motzer

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2012.06.009 ◽

2012 ◽

Vol 30 (5) ◽

pp. 748

Author(s):

Donald L. Trump

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Re: Comparative Effectiveness of Axitinib Versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

European Urology ◽

10.1016/j.eururo.2012.04.013 ◽

2012 ◽

Vol 62 (1) ◽

pp. 182-183 ◽

Author(s):

Patrick A. Kenney ◽

Christopher G. Wood

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

10.1016/s0140-6736(11)61613-9 ◽

2011 ◽

Vol 378 (9807) ◽

pp. 1931-1939 ◽

Cited By ~ 1195

Author(s):

Brian I Rini ◽

Bernard Escudier ◽

Piotr Tomczak ◽

Andrey Kaprin ◽

Cezary Szczylik ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13484037.793515464 ◽

2016 ◽

Author(s):

David M Nanus

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Comparative Effectiveness ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3427299 ◽

2019 ◽

Author(s):

Brian Rini ◽

Sumanta K. Pal ◽

Bernard J. Escudier ◽

Michael B. Atkins ◽

Thomas E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Phase 3 ◽

Open Label Study ◽

Download Full-text

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00693-8 ◽

2022 ◽

Author(s):

David Cella ◽

Robert J Motzer ◽

Cristina Suarez ◽

Steven I Blum ◽

Flavia Ejzykowicz ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Patient Reported Outcomes ◽

Advanced Renal Cell Carcinoma ◽

Phase 3 ◽

Patient Reported

Download Full-text

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc)

Annals of Oncology ◽

10.1093/annonc/mdx371.026 ◽

2017 ◽

Vol 28 ◽

pp. v307-v308

Author(s):

T. Powles ◽

R.J. Motzer ◽

D.J. George ◽

E. Jonasch ◽

S. Pal ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Phase 3 ◽

Plasma Biomarkers

Download Full-text

Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Kidney Cancer ◽

10.3233/kca-190080 ◽

2020 ◽

Vol 4 (1) ◽

pp. 29-39

Author(s):

Nizar M. Tannir ◽

Thomas Powles ◽

Bernard Escudier ◽

Frede Donskov ◽

Viktor Grünwald ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Clinical Outcomes ◽

Advanced Renal Cell Carcinoma ◽

Download Full-text

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Nature Medicine ◽

10.1038/s41591-020-1044-8 ◽

2020 ◽

Vol 26 (11) ◽

pp. 1733-1741 ◽

Author(s):

Robert J. Motzer ◽

Paul B. Robbins ◽

Thomas Powles ◽

Laurence Albiges ◽

John B. Haanen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Advanced Renal Cell Carcinoma ◽

Phase 3 ◽

Biomarker Analysis

Download Full-text